Monopar Therapeutics (MNPR) Net Income towards Common Stockholders (2017 - 2026)

Monopar Therapeutics has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$4.3 million in Q3 2025.

• Quarterly Net Income towards Common Stockholders fell 189.36% year-over-year to -$4.3 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$10.1 million (down 102.75% YoY) and the FY2025 annual result came in at -$13.7 million, up 11.45% from the prior year.
• Net Income towards Common Stockholders declined to -$4.3 million in Q3 2025 per MNPR's latest filing, from -$2.6 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$1.5 million in Q3 2024 and troughed at -$13.4 million in Q4 2022.
• A 5-year average of -$3.5 million and a median of -$2.5 million in 2021 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders jumped 31.6% in 2024, then tumbled 189.36% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$10.4 million in 2021, then slipped by 29.03% to -$13.4 million in 2022, then soared by 85.44% to -$2.0 million in 2023, then grew by 24.47% to -$1.5 million in 2024, then sank by 189.36% to -$4.3 million in 2025.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$4.3 million, -$2.6 million, and -$3.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.